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Overexpression of aminopeptidase A abolishes the growth 
promoting effects of angiotensin II in cultured mouse mesangial 
cells
G u n te r  W o l f ,  K a r e l  J.M. A ssm ann , and R o l f  A .K . S t a h l
Department o f Medicine, Division of Nephrology and Osteology, University of Hamburg, Hamburg, Germany; and Department of
Pathology, University Hospital Nijmegen, Nijmegen, The Netherlands
Overexpression of aminopeptidase A abolishes the growth promoting 
effects of angiotensin II in cultured mouse mesangial cells. Angiotensin II 
(Ang II) has diverse effects on the glomerular tuft such as regulation of 
glomerular hemodynamics and stimulation of mesangial cell growth, and 
may be one pivotal factor in the progression of renal disease. In order to 
locally inactivate Ang II, we overexpressed aminopeptidase A (E.C. 
3.4.11.7; AT A), a peptidase involved in the conversion of Ang II into 
angiotensin III, in a mouse mesangial cell line (MMC) that normally does 
not exhibit this enzyme. Stable transfections were selected in medium 
containing G418. ATA-overexpressing clones ATA5 and ATA21 revealed 
mRNA, protein, and enzyme activity in contrast to wild-type MMCs or 
mock-transfected Neo3 cells (stably transfected with expression vectors 
without ATA cDNA). There was no difference in the binding of Ang II to 
its putative receptors in all cell lines. Ang II increased intracellular inositol 
1,4,5-triphosphate (IP3) in Neo3, but not in ATA5 and ATA21 cells. In 
contrast to MMCs and Neo3 cells, Ang II failed to stimulate proliferation 
in ATA5 and ATA21 clones as measured by [3H] thymidine incorporation 
and direct cell counts. However, ATA5 and ATA21 revealed a mitogenic 
response not different from MMCs after stimulation 2% or 10% of fetal 
calf serum. Treatment of ATA5 and ATA21 with 0.1 mM of the ATA- 
inhibitor ainastatin or an ATA-inhibiting specific monoclonal antibody 
restored the proliferative effect of Ang II, suggesting that surface activity 
of ATA is involved in the attenuated mitogenesis in these cell. Our study 
demonstrates that it is feasible to overexpress Ang II-degrading enzymes 
in cultured mesangial cells and that this overexpression attenuated some 
effect of exogenous Ang II. These experiments are a first step toward the 
development of novel strategies to selectively antagonize locally generated 
Ang II in the kidney.
Angiotensin II (Ang II) is currently viewed as one major factor 
being involved in the progression of chronic renal disease [1- 8]. 
In the glomerular microenvironment, the octapeptide has been 
implicated in such diverse functions such as regulation of glomer­
ular hemodynamics and glomerular ultrafiltration, mesangial up­
take and processing of macromolecules, stimulation of mesangial 
growth and synthesis of extracellular matrix components such as 
collagens, and chemoattraction of immune competent cells into
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the glomerular tuft [1—7]. The most direct proof of the detrimental 
actions of Ang II on the glomerulus may stem from investigations 
in rats that overexpress angiotensinogen and renin in the glomer­
ulus [9]. These animals developed irreversible glomerulosclerosis 
without hypertension, suggesting that Ang II growth promoting 
effects may play a pivotal role in these structural alterations [9],
Although several substances, including angiotensin converting 
enzyme (ACE) inhibitors as well as the new non-peptide Ang 
Il-receptor antagonists, could effectively interfere with Ang II’s 
action, there is recent evidence of an independent renal renin- 
angiotensin system (RAS) that may not be necessarily inhibited by 
the commonly used concentrations of these drugs [3, 7].
In the present study, we have applied a different approach to 
locally inactivate Ang II. Cultured murine mesangial cells (MMC) 
were stably transfected with an expression plasmid in order to 
overexpress aminopeptidase A (E.C. 3.4.11.7; ATA). ATA is an 
Ang II degrading enzyme and is normally expressed in the kidney 
in mouse podocytes as well as proximal tubular epithelia cells, but 
not in mesangial cells [10]. The overexpression of ATA in MMCs 
abolished the mitogenic action of Ang II normally observed in 
these cells, but was without effect on Ang II-receptor expression 
or proliferative response induced by other mitogens. Our studies 
demonstrate that it is feasible to overexpress an Ang II-splitting 
enzyme to antagonize the actions of this vasopeptide presumably 
by its faster degradation.
METHODS
Cell culture
Mouse mesangial cells (MMCs) a re  a SV 40-transformed cell 
line originally isolated from 8- to 10-week-old naive SJL/J (H-2h) 
mice [11]. These cells possess many features of differentiated 
mesangial cells including expression of Ang II-receptors and a 
Fc-receptor for immunoglobulins, and have been extensively 
characterized [11-14]. MMCs were grown in Dulbecco’s Modified 
Eagle’s medium (DMEM; Gibco-BRL, Eggenstein, Germany) 
containing 450 mg/dl glucose, 100 U/ml penicillin, 100 fxg/ml 
streptomycin, 5 mM glutamine, and 10% decomplemented fetal 
calf serum (FCS; Gibco-BRL). Cells were grown in 5% C 0 2 afld 
passaged every 48 to 72 hours by trypsinization.
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Transfection procedures and selection of ATA overexp res sing
clones
For ATA overexpression, 106 MMCs were cotransfected with 
10 /xg of each SRaBP-1 (gift of Max D. Cooper, University of 
Alabama, Birmingham, AL, USA) [15] and 5 ¡jlg pHook-1 (In- 
vitrogen, Leek, Netherlands) using calcium phosphate. The 
SRaBP-l plasmid contains a full-length cDNA encoding for BP-1, 
the mouse ATA, driven by the SRa promoter that is composed of 
the SV 40 early promoter and the R segment, and is part of the U5 
sequence of the long terminal repeat o f human T-cell leukemia 
virus type I [16]. The SRaBP-1 construct has been previously used 
to express ATA in COS-7 and Ltk~ cells [15]. Besides a neomycin 
resistance, the pHook-1 plasmid expresses a single-chain antibody 
(sFv) to a specific hapten (see below) being displayed on the 
surface of transfected cells. Twenty-four hours after transfection, 
cells were released from the plate by light trypsinization, washed, 
and were collected in a 1.5 ml cup. Cells were mixed with 1.5 x 
10fi magnetic beads bearing the phOx (4-rthoxy-methylene-2- 
phenyl-2-oxazolin-5-one) hapten on their surface (Capture beads; 
Invitrogen). After incubation with slow rotation (5 revolutions per 
min) for 30 minutes at 37°C, the beads were pelleted with a 
magnetic stand' (Invitrogen). Non-selected cells were removed, 
pellets were washed in serum-free DMEM, and the pelleting was 
repeated with the magnetic stand. This washing step was repeated 
twice. Finally, cells were plated at low-density into a 96-well plate 
in DMEM with 10% FCS. After another 24 hours, the medium 
was changed and 600 fig/ml of G418 (Gibco-BRL) were added to 
select for stable transfectants. In pilot experiments we established 
that this concentration of G418 was toxic for wild-type MMCs. 
After one week, surviving cells were cloned by limiting dilution 
and replated in 96-well plates in the presence of G418. Estab­
lished cultures were maintained in medium with 600 jug/ml G418 
to prevent back mutations. In general, no G418 was used for 
proliferation experiments and enzyme measurements.
In addition, control cell lines were established by transfecting 
MMCs with an SRa vector [16] without a BP-1 insert and the 
pHook-1 plasmid. Selection of sFV bearing cells and limiting 
dilution in G418 containing medium was performed as described 
above. Control cell lines were designated as Neo.
RT-PCR for aminopeptidase A and Northern blotting
Stable transfectants were initially screened for ATA transcripts 
by cDNA amplification of reverse transcribed total RNA. There­
fore, a total of 106 cells were lysed in 5 ml of a buffer containing
4 m  guanidine thiocyanate, 25 m M  sodium citrate (pH 7.0), 0.5% 
sodium lauroyl-sarcosinate, and 0.7% /3-mercaptoethanol. Total 
RNA was extracted by repetitive phenol-chloroform extraction 
and was precipitated with ice-cold isopropranolol [12]. For re­
verse transcription, 5 fig of total RNA in 7.5 ¡A water were 
incubated at 65°C for three minutes, and subsequently 5.5 ¡A 
first-strand buffer (250 m M  Tris-HCl, 375 m M  KC1,15 mM  MgCl2), 
3.4 ¡A deoxynucleotide triphosphates (dNTP, 10 m M  of each), 2.7 
t^l 0.1 m  dithiothreitol, 0.5 ¡ig Poly-dT-primer (Pharmacia, 
Freiburg, Germany), 14 U RNAsin (Promega, Madison, WI, 
USA), and 200 U M-MLV Reverse Transcriptase (Gibco-BRL) 
were added, and the reaction was incubated at 37°C for 90 
minutes. After first-strand cDNA synthesis, the reaction mix 
was precipitated with 7.5 m  ammonium acetate and isopropanol. 
The pellets were washed in 70% ethanol and resuspended in
50 rd water. Five microiiters of each cDNA and 150 ng of the 
following primers were used: mouse ATA, 5'GACGTACTTTC-
AAGGCCAAGTG35'GCTGCAGTTCAGTGTTGAAGGG3' 
[17]; GAPDH, 5' A AT G CAT CCT GC ACC AC CA A3', 5'GTAGC- 
CATATTCATTGTCATA3' [18]. The predicted sizes of the 
amplification reactions were 563 bp for ATA, and 521 bp for 
GAPDH. Amplification reactions were performed exactly as 
described previously [19] with 0.2 m of each dNTP and 2.5 U of 
Taq polymerase (Perkin Elmer Cetus, Ueberlingen, Germany) in 
amplification buffer (20 mM Tris-HCl, pH 8.3; 25 mM KC1, 2.0 mM 
MgCl2, 0.05% Tween 20). Amplifications for mouse ATA and 
GAPDH was performed in separate tubes. Thirty-five cycles with 
a denaturation step for 92°C for one minute, an annealing step of 
56°C for 1.5 minutes, and an extension step at 72°C for 1.5 minutes 
were performed. Ten microiiters of each reaction product were 
run on a 1.5% agarose gel containing 0.5 ¿¿g/ml ethidium bromide.
To confirm the results obtained from RT-PCR by Northern 
blotting, 20 jug of total RNA was electrophoresed through a 1.2% 
agarose gel with 2.2 M formaldehyde. The RNA was vacuum 
blotted onto a nylon membrane (Zetabind; Cuno, Meriden, CT, 
USA) and UV cross-linked. For the detection of mouse ATA 
transcripts, a 3.5 kilobase fragment of the cDNA BP-1 (also a gift 
of Max D. Cooper) [17] was labeled using random primers. For 
control hybridization after stripping, a 2.0 kilobase insert of the 
plasmid pMCl encoding the mouse 18S RNA band was used. 
Hybridization, washing, and stripping procedures were performed 
exactly as previously described [12, 13],
Angiotensin II-receptor expression
To test whether ATA overexpressing cells may exhibit a differ­
ent expression pattern of Ang II-receptors, RT-PCR for the 
ATr receptor as well as competition binding studies were per­
formed, RT-PCR was executed for 35 cycles a.s described above 
(same temperature profile) with the following primers for the 
AT l -receptor: 5' GAT A ATTATGGCG ATTGT G3' and 5'GTA- 
AGAAAGCGTGCTCATTTTCG3' [20]. The predicted size of 
the amplified product was 238 bp. Hybridization of an end labeled 
internal primer to the amplification product revealed the correct 
nature of the product (data not shown). For control reactions, the 
following primers for mouse j3-actin were used: 5'GGCCAAGT- 
CATCACTATTG G3' and 5' GGACTCATCGTACTCCTGC3'. 
Reactions were independently (RNA isolation, reverse transcrip­
tion, and cDNA amplification) performed four times with quali­
tatively similar results.
Binding studies were carried out on 5 X 104 cells grown to 
subconfluence in 24-well culture plates in assay buffer consisting 
of 150 mM NaCl, 5 mM MgCl2, 50 mM Tris-HCl (pH 7.1), 5 mM 
EDTA, 0.7% bovine serum albumin, 0.5% aprotinin, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), and 0.5 mM amastatin 
(Sigma, Deisenhofen, Germany) to inhibit potential ATA activity 
in overexpressing clones [21], For displacement experiments, 0.5 
pM [tyrosyl-3,5-3H]-angiotensin II (30 to 60 Ci/mmol; Amersham, 
Braunschweig, Germany) was incubated in the presence or ab­
sence of 10~9 to 10-7  m cold Ang II (Sigma) for two hours on a 
shaking platform at 22°C. At the end of the incubation period, 
cells were washed three times in ice-cold PBS, precipitated in 10% 
trichloracetic acid, and proteins were redissolved in 1 n  NaOH. 
Radioactivity was determined by liquid scintillation spectroscopy. 
Nonspecific binding was determined in the presence of 10 ~5 m 
non-radioactive Ang II and was less than 10% of total binding.
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Specific binding in the absence of cold competitor was considered 
to be 100%. Experiments were repeated four times with duplicate 
measurements for each experiment.
Aminopeptidase A enzyme activity
Aminopeptidase A (ATA) surface enzyme activities were mea­
sured on subconfluent cells in 24-well plates rested for 24 hours in 
serum-free DMEM, For this reason, lO^  cells were incubated for 
one hour in 1 ml of a substrate solution containing 17,5 mM 
alpha-glutamyl-nitranilide (Serva, Heidelberg, Germany) in 0.5 m 
Tris-HCl (pH 7.2) supplemented with 10 mM calcium chloride. At 
the end of the incubation, cells were washed in PBS, lysed, and the 
protein content was determined by the Lowry method. Absorption 
of substrate solution was immediately measured at 405 nm against 
the substrate solution as blank. ATA activity was calculated as 
described and is expressed in ju,U/mg cellular protein [22],
Western blotting
A total of 107 quiescent cells of the various clones were washed 
in ice-cold PBS and scraped off the culture flask in disruption 
buffer (2% SDS, 60 mM Tris-HCl, pH 6.8; 100 mM dithiothreitol, 
0.5% aprotinin, and 0.5 mM PMSF). Protein concentrations were 
adjusted to 100 ¡¿g/sample, 5% glycerol/0.03% bromophenol blue 
were added, and samples were boiled for 10 minutes. After 
centrifugation, supernatants were loaded onto a denaturing 8% 
SDS-polyacrylamide gel. Molecular weight markers (High molec­
ular Rainbow markers, Amersham) that comprise 14,300 to 
200,000 Daltons served as molecular weight standards. After 
completion of electrophoresis, proteins were electroblotted onto a 
nitrocellulose membrane (Highbond-N; Amersham) in transfer 
buffer (50 mM Tris-HCl, pH 7.0; 380 mM glycine, 0.1% SDS, 20% 
methanol). Membranes were blocked for one hour at 22°C with 
5% nonfat dry milk redissolved in PBS with 0.1% Tween 20. For 
the detection of ATA, a 1:500 dilution of the rat monoclonal 
antibody ASD-4 generated against mouse ATA was used as a 
primary antibody. The generation and characterization of this 
antibody has been previously described [23, 24], A horseradish 
peroxidase-conjugated polyclonal rabbit anti-rat antibody (Sigma) 
was used as a secondary antibody. The ECL reagent (Amersham) 
was applied according to the recommendations of the manufac­
turer to visualize peroxidase. Western blots were repeated twice.
Immunofluorescence
Cells were grown in glass slide chambers (Nunc, Roskilde, 
Denmark) to subconfluence. Cells were then fixed at -20°C in 
acetone for 10 minutes before their staining. Slides were incu­
bated with a 1:20 dilution of the monoclonal ASD-4 antibody for 
one hour in a wet chamber. After washing in PBS with 0.5% 
albumin, the stain was developed with a 1:50 diluted FITC-labeled 
rabbit anti-rat IgG antiserum (Miles Scientific, Munich, Germa­
ny).
Intracellular inositol trisphophate concentrations
ATA5, ATA21 and Neo3 cells (2 X 105) were plated into 
six-well plates, rested for 24 hours in serum-free medium, and 
subsequently stimulated for 10 minutes with 10“ 6  m Ang II. In 
addition, to inhibit ATA enzyme activity in ATA21cells, 20 jxl of 
ascites of the monoclonal anti-murine ATA antibody ASD-4 were 
added per well 30 minutes prior to challenge with control medium 
or Ang II. This antibody has been previously shown to inhibit
ATA enzyme activity [23, 24]. Some ATA21 cells were also 
treated with 10 m of angiotensin III (Ang III; Sigma). The 
incubation was terminated with 15% trichloracetic acid, and 
supernatants of lysed cells were extracted three times with 10 vol 
water-saturated diethyl ether and then titrated to pH 7.5 with 1 u 
NaHC03. Cells were counted in parallel wells. Intracellular 
inositol 1,4,5-trisphosphate (IP3) was measured in duplicate from 
each experiment (N  = 4 to 5 independent experiments) directly in 
the neutralized supernatants with a commercial radioimmunoas­
say according to the manufacturer’s recommendations (Biotrak" 
from Amersham). Data are expressed as picomoles of IP3 per 105 
cells.
Cellular proliferation
A total of 104 cells of the various lines were transferred to each 
well of a 96-well plate and were made quiescent in DMEM 
without PCS and G418. Cells were then incubated for 24 hours 
with a single dose of I0-s  to 10 _ 6 m Ang II. This dose was shown 
earlier to be mitogenic for MMCs [J1 ,12]. To test for the effect of 
ATA expression, enzyme activity was inhibited for some experi­
ments with 0.1 mM amastatin. In order to inhibit ATA more 
specifically, ATA5 and ATA21 cells were incubated in the pres­
ence of 2 ¿¿I per well (96-well plate) of ascites of the monoclonal 
anti-murine ATA antibody ASD-4. For these experiments, cells 
incubated in control medium without Ang II also received the 
same amount of antibody to control for nonspecific effects. 
Additional cells received DMEM with either 2% or 10% FCS. 
Moreover, all cell lines were also treated with a single dose of 
either Ang III or angiotensin IV (Ang ll-(3-8) = Ang IV; Sigma). 
Cells were pulsed with 1 fiC i per well [3H]thymidine (5 Ci/mmol, 
Amersham) for the last six hours of culture. At the end of the 
incubation, cells were washed once in PBS, trypsinized for 10 
minutes at 37°C, and finally collected on glass-fiber paper with an 
automatic cell harvester. Radioactivity of dry filters was deter­
mined by liquid scintillation spectroscopy in the presence of 
scintillation cocktail (Roth, Karlsruhe, Germany). [3H] thymidine 
incorporation experiments were independently repeated five to six 
times in duplicate. For direct cell counts, 105 cells were trans­
ferred into each well of a 24-well plate, rested for 24 hours in 
serum-free DMEM without G418, and stimulated for another 48 
hours with 10 7 to 1 0 '6 m Ang II. At the end of the incubation 
period, cells were trypsinized, and counted in a Neubauer cham­
ber by an investigator blinded to the protocol. Direct ceil count 
experiments were independently repeated six times in duplicate.
Statistical analysis
All data are presented as the means ± sem. Statistical signifi­
cance between different groups was first tested with the non- 
parametric Kruskal-Wallis test. Individual groups were subse­
quently tested using the Wilcoxon-Mann-Whitney test. A P value 
of < 0.05 was considered significant.
RESULTS
Establishment and characterization of aminopeptidase A 
overexpressing mesangial cells
A total of twenty surviving G418 clones were screened  by 
RT-PCR two weeks after transfection. From these clones, seven 
showed an amplification product of the expected 563 base pairs. 
Figure 1 shows an example of a cDNA amplification after reverse
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Fig. 6. [3H] thymidine incorporation into DNA 
as one measurement of proliferation. Cells were 
incubated for 24 hours with a single dose of 
10~8 to 10' 6 m Ang II in the absence of other 
factors. As predicted from earlier experiments 
[11], Ang II stimulated proliferation in MMCs 
(□ ) and mock-transfected Neo3 cells (□). 
However, the vasoactive peptide failed to 
induce mitogenesis in ATA5 (E3) and ATA21 
(■) cells. There was even a tendency in ATA5 
cells that ANG II may cause inhibition of 
proliferation, although the values did not reach 
statistical significance. N  =  10, *P <  0.05 versus 
unstimulated controls.
Table 3. Effect of FCS (10% or 2%) on [3H] thymidine incorporation
Cell line
Controls 10% FCS 2 % FCS
XjO4 cpm
MMC 7.1 ± 0.7 120.1 ± 3.1b 15.2 ± 1.0°
ATA5 9.4 ± 0.9 102.3 ± 2.0b 17.0 ± 2.1a
ATA21 4.7 ± 0.4 115.9 ± 5.3b 10.1 ± 0 ,8°
N  = 8 to 10.
a P <  0.01, h P <  0.001 versus controls
Table 4. Effect of 0.1 mM amastatin on Ang II-stimulated [3H] 
thymidine incorporation in ATA5 and ATA21 cells
[3H] thymidine
Cell line X104 cpm
ATA5
Controls 7.0 ± 0.6
Controls + amastatin 4.7 ± 0.4
10~7 M Ang II 6.8 ± 0.4
10“ 7 M Ang II + amastatin 8.0 ± 1.3
ATA21
Controls 5.8 ± 0.5
Controls + amastatin 7.5 ± 0.9
IO" 7 M Ang II 6.6 ±  0.5
10~7 M Ang II -1- amastatin 12.1 ±  1.0
II p
a P <  0.05 versus controls + amastatin
antagonize Ang IPs effects. However, the currently employed 
drugs to intervene with the RAS may have some disadvantages. 
For example, it remains unclear whether ACE inhibitors in the 
commonly used dosage totally inhibit local tissue ACE activity 
[2-4]. In addition, ACE may be bypassed and active Ang IT can be 
formed by other enzymes such a chymase [47]. On the other hand, 
blockade of the AT j-receptor may shift binding of Ang II to other
Table 5. Effect of a neutralizing anti-murine ATA monoclonal antibody 
on Ang II-stimulated [3H] thymidine incorporation in ATA5 and
ATA21 ceils
Cell line X 1 0 4 cpm
ATA5
Controls + moAb 8.1 ± 0.7
10-6  M Ang II 6.5 ± 0.5
10”rt M Ang II + moAb 10.2 ± 0.6a
ATA2I
Controls + moAb 7.0 ± 0.9
10“ fi M Ang II 6.8 ±  0.5
10“ A M Ang II +  moab 12.2 ±  1.1“
Abbreviations are: Ang, angiotensin; moAb, neutralizing anti-ATA 
monoclonal antibody. 
a P <  0.05 versus Ang II only
receptors including AT2 [48]. Although this effect could be 
protective since AT2-receptor activation has been associated with 
antigrowth effects in some tissue [49,50], there is little evidence of 
this mechanism in renal tissue. Furthermore, we have recently 
provided evidence that stimulation of AT2-receptors in glomeru­
lar endothelial cells induces the synthesis of the chemokine 
RANTES, a strong chemoattractant substance for macrophages/ 
monocytes [51]. Treatment with ACE inhibitors as well as with 
ATr receptor antagonists stimulates renin synthesis. Recent evi­
dence suggests that renin directly binds to mesangial cells, stim­
ulates proliferation, and increases plasminogen activator inhibi­
tor-1 antigen, which are undesired effects that may occur during 
hyperreninemia [52]. Thus, overexpression of ATA spatially ad­
jacent to Ang II-receptors may locally inactivate Ang II without 
influencing RAS, providing some advantages over other therapeu­
tic manipulations. However, since Ang III, the product of ATA- 
mediated Ang II metabolism, may also bind to AT,-receptors, 
ATA over expression in vivo would be only successful if Ang III is 
directly further cleaved to inactive fragments. In addition, we have
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Table 6. Effect of angiotensin III (Ang III) and angiotensin IV (Ang
IV) on [3H] thymidine incorporation
Cell line X Si
MMC
Controls 8.5 ± 0.6
iÜ~6 M Ang III 9.1 ± 0.5
10"r’ m  Ang IV 8.2 ±  0.2
Neo3
Controls 6.5 ± 0.6
1 0 m Ang III 7.0 ± 0.8
lü" 6 M Ang IV 6.0 ±  0.7
ATA5
Controls 8.0 ±  0.2
10" 6 M Ang III 6.7 ± 0.2
10 6 M Ang IV 9.0 ± 0.3
ATA21
Controls 7.9 ± 0.5
l0 - ( ‘ m  Ang III 7.5 ± 0.2
10“ 6 M Ang IV 8.3 ± 0.7
N  = 10 to 12.
overexpressed ATA in SV 40-transformed mesangial cells and it is 
currently unclear if this enzyme could be adequately overex­
pressed in normal mesangial cells residing in the glomerular 
microenvironment. Therefore, it remains to be established 
whether ATA-overexpression may be effective in vivo.
In summary, overexpressing of ATA in mesangial cells abol­
ished the proliferative effects of Ang II on these cells. Our 
experiments are a first step toward the development of novel 
strategies to selectively interfere with a locally activated RAS.
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APPENDIX
Abbreviations used in this study are: Ang, angiotensin; ATA, amino- 
peptidase A; MMC, mouse mesangial cell line; RAS, renin-angiotensin 
system; IP3, 1,4,5-triphosphate; ACE, angiotensin converting enzyme; 
PBS, phosphate buffered saline; dNTP, deoxynucleotide triphosphate; 
PMSF, phenylmethylsulfonyl fluoride.
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